Small Cap IR Initiates Coverage of Can-Fite Biopharma: Newly Discovered Late Clinical Stage BioPharma Vendor with Potentially Revolutionary Breakthroughs
NEW YORK, Nov. 19, 2014 /PRNewswire/ -- Analyst report by Small Cap IR - Can-Fite BioPharma Ltd. (NYSEMKT: CANF) is an advanced clinical stage drug development company with a platform technology that addresses multi-billion markets in the treatment of inflammatory diseases, cancer, sexual dysfunction, and ophthalmic indications. The Company is conducting Phase I, II and III clinical trials for numerous indications in the U.S., Europe and Israel. Can-Fite currently maintains 14 patent families that include 74 international patents issued and pending and its science is well-founded with articles in 48 peer reviewed journals.
The Company's drug candidates are primarily small molecule products which can be a significant advantage in certain indications. The company principally develops CF101 that is in Phase III study for the treatment of psoriasis, as well as completed Phase II study for the treatment of rheumatoid arthritis; completed Phase III study for the treatment of dry eye; completed Phase II study for the treatment of glaucoma; and initiating a Phase II study of CF101 for the treatment of uveitis. It also develops CF102, which is in Phase II study for the treatment of liver cancer; and CF602 that has completed pre-clinical trial for the treatment of inflammatory diseases. The company is headquartered in Petah-Tikva, Israel.
CANF appears to be a relatively undiscovered and underappreciated gem in BioPharma which now has a chance to come into its own as a developer and marketer of small molecule drugs for multiple indications. CANF's strategy is to build a fully integrated biotechnology company that discovers, in-licenses and develops an innovative and effective small molecule drug portfolio of ligands that bind to a specific therapeutic target for the treatment of autoimmune-inflammatory, oncological, ophthalmic diseases and more. We believe CANF's pipeline of drug candidates represent a significant market opportunity.
In addition to the very large available markets, validated unmet needs and milestones approaching we want to also be aware of hidden value in retained shares of a spinoff company that could pay off similar to the way Yahoo benefited from Alibaba shares. The Company's diversified asset portfolio includes a large stake in spinout OphthaliX. CANF spun out the ocular indications for CF101 to OphthaliX Inc. and still retains 82% ownership of the company.
An analyst report which includes an overview of the company, financial and competitive analysis, analyst recommendation and price target can be viewed in its entirety by using the link below. There is no cost obligation required to view this report.
Small Cap IR was the first firm to notify its members of CANF on 11-18-2014 with a full due diligence report before market open.
http://bit.ly/-CANF-AnalystValuation
Copy and paste to browser may be required.
About Small Cap IR
Once you have read our reports written by financial analysts you will understand that we make every effort to provide informative equity research reports for interested parties.
3rd party chartered financial analysts (CFA's) provide a straightforward assessment of the profiled company and have pledged to remain free of influence when writing research reports. They include stocks traded in the NYSE, NASDAQ, and OTCBB exchanges.
Forward-Looking Disclaimer
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.
Compliance Procedure
Content is researched, written and reviewed on a best-effort basis by a 3rd party research analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. We do not engage in high frequency trading.
A full disclaimer can be found by viewing the analyst report.
If you wish to have a company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected]. For any urgent concerns or inquiries please contact us at [email protected].
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
Contact: [email protected]
SOURCE Small Cap IR
Share this article